Lotemax Shortage: What Providers and Prescribers Need to Know in 2026

For eye care providers, Lotemax (loteprednol etabonate) is a cornerstone of post-surgical and inflammatory ocular disease management. While no FDA-declared shortage currently exists for loteprednol products as of 2026, you're likely seeing patients who struggle to fill their prescriptions due to formulary barriers, localized stocking variability, and cost. This guide gives you the clinical and operational context you need to manage these situations proactively.

Current Availability Status: What the Data Shows

As of 2026, loteprednol etabonate products are not listed on the FDA Drug Shortages database. However, "no official shortage" does not translate to seamless patient access. The key access barriers include:

Formulary exclusions: Most commercial insurance plans and Medicare Part D either exclude brand-name Lotemax entirely or place it on Tier 3–4 with prior authorization requirements.

Step therapy mandates: Some plans require patients to fail on prednisolone acetate before authorizing loteprednol — a requirement that is clinically inappropriate in post-surgical patients where an immediate, specific drug is part of the surgical care plan.

Pharmacy-level stocking gaps: Brand-only formulations (gel, ointment, SM) are stocked in limited quantities at community pharmacies. Regional distribution disruptions or post-surgical demand spikes can create localized unavailability.

Cash price barriers: Retail prices of $155–$440+ create real access barriers for uninsured and underinsured patients. Non-adherence to post-surgical regimens due to cost is an underappreciated risk factor for complications.

Pharmacology Refresher: Why Loteprednol Is the Preferred Choice

Loteprednol etabonate is a retrometabolically designed corticosteroid with a unique ester at C-20 that undergoes rapid conversion to an inactive carboxylic acid metabolite (PJ91) in the eye. This retrometabolic design results in minimal systemic absorption (<1 ng/mL in pharmacokinetic studies) and a significantly lower IOP-elevation profile compared to prednisolone acetate and dexamethasone.

For patients who are known steroid responders, have a history of ocular hypertension, or have glaucomatous damage, the lower IOP risk of loteprednol makes it the clinically preferable option. Post-surgical selection of loteprednol over prednisolone in these risk groups is evidence-based and medically necessary — a distinction worth documenting when filing prior authorization requests.

Navigating Prior Authorization for Lotemax

When insurance requires PA for Lotemax, your clinical documentation should emphasize:

The specific indication (post-cataract surgery is typically the most approvable)

Patient risk factors that make prednisolone acetate medically inappropriate (glaucoma diagnosis, prior steroid response, elevated baseline IOP)

The time-sensitive nature of post-surgical care — step therapy delays are clinically harmful

Refer to FDA-approved labeling for post-operative use as the primary indication

Evidence-Based Substitution When Lotemax Is Unavailable

When Lotemax cannot be obtained, the substitution decision should be based on the clinical indication and patient risk profile:

Standard-risk post-surgical patients: Prednisolone acetate 1% QID × 2–4 weeks with IOP monitoring at follow-up is appropriate.

High-risk patients (glaucoma, steroid responders): Consider Dextenza (intracanalicular dexamethasone insert) for no-drop compliance, or fluorometholone with closer follow-up.

Complex surgeries with high inflammatory burden: Difluprednate (Durezol) BID may be appropriate with close IOP monitoring, particularly if inflammation control is the primary concern.

Helping Patients Access Lotemax Through Savings Programs

When insurance won't cover Lotemax, directing patients to savings programs can preserve your intended treatment plan:

Bausch + Lomb Access Program: Uninsured patients as low as $69/fill; commercially insured as low as $25–$35 at Walgreens or participating pharmacies (bauschcopayprogram.com, 1-866-693-4880).

Bausch + Lomb Part D Program: Medicare Part D patients as low as $79/fill (blpartdcoupon.com).

GoodRx: Lotemax suspension as low as $49 with GoodRx coupon at many pharmacies.

Supporting Your Patients in Finding the Medication

Consider directing patients to medfinder for providers — a service that contacts pharmacies near the patient to identify which ones can fill their prescription. This reduces the administrative burden on your front office and ensures patients don't skip their post-surgical drops due to access barriers.